Jiangsu Recbio Technology Co., Ltd. (2179.HK)

9.160 -0.010 (-0.11%) As of 01:50PM HKT. Market open.

Jiangsu Recbio Technology Co., Ltd.

No. 888 Yaocheng Avenue
Medical High-tech District
Taizhou
China

https://www.recbio.cn

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 472

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Yong Liu	Founder, CEO & Chairman of the Board	3.07M	N/A	1973
Ms. Qingqing Chen	CFO, Secretary of Board & Executive Director	2.16M	N/A	1983
Dr. Kunxue Hong	Chief Science Officer & Executive Director	2.17M	N/A	1965
Mr. Bu Li	Chief Human Resource Officer & Executive Director	2.15M	N/A	1977
Mr. Yang Zhou	Chief Operating Officer	N/A	N/A	N/A
Mr. Kejian Yang	Chief Technology Officer	N/A	N/A	N/A
Mr. Hongjun Zhou	Vice General Manager	N/A	N/A	1981
Ms. Jing Wang	Chief Quality Officer	N/A	N/A	N/A
Mr. Lei Zhou	Finance controller	N/A	N/A	1986
Ms. Yin Kwan Ho	Joint Company Secretary	N/A	N/A	1978

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.

Description

Jiangsu Recbio Technology Co., Ltd., a vaccine company, engages in the research, development, and commercialization of subunit vaccines in the People's Republic of China. The company is developing vaccines for the treatment of cervical cancer, and anal and genital warts, including REC603, a recombinant human papillomavirus (HPV) 9-valent vaccine that is in phase III clinical trial; REC601 and REC602 recombinant HPV bivalent vaccines, which are in phase I clinical trials; REC604a, a recombinant HPV quadrivalent vaccine that is in pre-clinical stage; and REC604b, a recombinant HPV 9-valent vaccine that is in pre-clinical stage. It also develops ReCOV, a recombinant COVID-19 vaccine candidate that is in Phase II/III trial; R520A, a messenger ribonucleic acid COVID-19 vaccine candidate that is in pre-clinical stage; REC610, a recombinant shingles vaccine that is in Phase l clinical trial; REC607, a virus vectored adult tuberculosis vaccine that is in pre-clinical stage; REC606, a recombinant adult tuberculosis vaccine that is in pre-clinical stage; REC617, a recombinant influenza quadrivalent vaccine that is in pre-clinical stage; and REC605, a recombinant hand-foot-mouth disease quadrivalent vaccine that is in pre-clinical stage. Jiangsu Recbio Technology Co., Ltd. was founded in 2011 and is headquartered in Taizhou, the People's Republic of China.

Corporate governance

Jiangsu Recbio Technology Co., Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.